Clinical Trial News and Research RSS Feed - Clinical Trial News and Research

TauRx achieves target enrolment in second LMTX Phase III clinical trial for Alzheimer's disease

TauRx achieves target enrolment in second LMTX Phase III clinical trial for Alzheimer's disease

TauRx Therapeutics Ltd has achieved its target enrolment of 700 subjects with mild Alzheimer's disease into the second of its two Phase III clinical trials of LMTX, a tau aggregation inhibitor, for the treatment of Alzheimer's disease. [More]
Researchers test novel robotic system to improve prostate cancer biopsies

Researchers test novel robotic system to improve prostate cancer biopsies

A novel robotic system that can operate inside the bore of an MRI scanner is currently being tested as part of a biomedical research partnership program at Brigham and Women's Hospital in Boston with the aim of determining if the robot, in conjunction with real-time MRI images, can make prostate cancer biopsies faster, more accurate, less costly, and less discomforting for the patient. [More]
Dry roasted peanuts more likely to trigger allergy risk

Dry roasted peanuts more likely to trigger allergy risk

Dry roasted peanuts are more likely to trigger an allergy to peanuts than raw peanuts, suggests an Oxford University study involving mice. [More]
GWU researcher receives AHA grant to study diffuse brain swelling, injury in ICH patients

GWU researcher receives AHA grant to study diffuse brain swelling, injury in ICH patients

Shahram Majidi, M.D., a second-year resident in the Department of Neurology at the George Washington University School of Medicine and Health Sciences, received at $154K grant from the American Heart Association to study the presence of diffuse brain swelling and injury in patients with intracerebral hemorrhage (ICH). [More]
Soligenix awarded $24.7 million contract to advance development of Rivax vaccine

Soligenix awarded $24.7 million contract to advance development of Rivax vaccine

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has been awarded a contract valued at up to $24.7 million inclusive of options by the US Department of Health and Human Service's National Institutes of Health (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID). [More]
PCI acquires Biotec Services International

PCI acquires Biotec Services International

PCI is pleased to announce it has acquired Biotec Services International. Biotec is a leading provider of Clinical Trial Services and Temperature Controlled Pharmaceutical Services headquartered in Bridgend, Wales in the United Kingdom. [More]
Reducing insomnia can decrease inflammation, lower risk for chronic disease in older adults

Reducing insomnia can decrease inflammation, lower risk for chronic disease in older adults

Lack of sleep can make you sick. And while everybody has the occasional restless night, for those who suffer from chronic insomnia — some 15 percent of older adults in the United States — that sleep loss can increase the risk for cardiovascular disease, hypertension, weight gain, type 2 diabetes, and even lead to an earlier death. [More]
Penn Medicine, Wistar Institute awarded NCI grants for four new melanoma research projects

Penn Medicine, Wistar Institute awarded NCI grants for four new melanoma research projects

Penn Medicine and The Wistar Institute have been awarded a prestigious $12.1 million SPORE grant from the National Cancer Institute. The five-year Specialized Programs of Research Excellence, or SPORE, grant will fund four new melanoma research projects that aim to translate fundamental laboratory discoveries into new therapeutics to treat melanoma and other skin cancers. [More]
Acclarent releases ACCLARENT AERA Eustachian Tube Balloon Dilation System for ETD treatment

Acclarent releases ACCLARENT AERA Eustachian Tube Balloon Dilation System for ETD treatment

Acclarent, Inc. announced today the launch of the ACCLARENT AERA Eustachian Tube Balloon Dilation System for the treatment of adult patients with Eustachian Tube Dysfunction (ETD), a condition marked by ear pain, pressure and dulled hearing. [More]
Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Immune Pharmaceuticals Inc. announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of ulcerative colitis (UC). [More]
Benefits and risks of hatha yoga for people with bipolar disorder

Benefits and risks of hatha yoga for people with bipolar disorder

Right now no one can say whether yoga provides clinical benefits to people with bipolar disorder, but in a new article in the Journal of Psychiatric Practice, researchers report survey responses they gathered from scores of people with the condition who practice yoga. What the collective testimony suggests is that yoga can be a substantial help, but it sometimes carries risks, too. [More]
Radiation and endocrine therapy combination may not be necessary for all HR+ breast cancer patients

Radiation and endocrine therapy combination may not be necessary for all HR+ breast cancer patients

Treatment with endocrine therapy and radiation therapy as part of breast conservation is the current standard of care for women with hormone-receptor positive (HR+) invasive breast cancer. A new study by researchers at Fox Chase Cancer Center, however, shows that combination may not be necessary for all patient populations with the disease. [More]
Vercise DBS System receives CE Mark approval for treatment of essential tremor

Vercise DBS System receives CE Mark approval for treatment of essential tremor

Boston Scientific Corporation has received CE Mark for the Vercise Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement disorder known as essential tremor (ET). [More]
Janssen announces availability of PREZCOBIX for Canadians living with HIV

Janssen announces availability of PREZCOBIX for Canadians living with HIV

Janssen Inc. announced today that PREZCOBIX (darunavir/cobicistat), a once-daily, oral medication for the treatment of HIV infection in combination with other antiretroviral agents, is now available in Canada. It is the first HIV treatment option available to patients that provides boosted darunavir in a single tablet. [More]
UCSD researchers launch phase 1 trial to assess novel monoclonal antibody for CLL patients

UCSD researchers launch phase 1 trial to assess novel monoclonal antibody for CLL patients

Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults. [More]
Adding common epilepsy drug to morphine can result in better pain control, say IU researchers

Adding common epilepsy drug to morphine can result in better pain control, say IU researchers

Adding a common epilepsy drug to a morphine regimen can result in better pain control with fewer side effects. Moreover, the combination can reduce the dosage of the opioid needed to be effective, according to a team of pain researchers at Indiana University. [More]
Milk consumption and dairy may lower blood pressure, CVD risk

Milk consumption and dairy may lower blood pressure, CVD risk

Globally, cardiovascular disease (CVD) claims 17 million lives each year, while complications from high blood pressure take an additional 9.4 million. New research presented by international scientists at the 12th Euro Fed Lipid Congress in Montpellier, France on September 15, 2014, suggests that milk consumption and dairy may play a beneficial role. [More]
Denovo gains all rights from Lilly to develop, manufacture and commercialize enzastaurin drug

Denovo gains all rights from Lilly to develop, manufacture and commercialize enzastaurin drug

Denovo Biopharma, LLC, today announced that it has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly and Company. Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all intellectual property and other rights, data, and information. [More]
MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Nektar Therapeutics reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. [More]
Lilly, AstraZeneca partner to co-develop and commercialize potential Alzheimer's disease treatment

Lilly, AstraZeneca partner to co-develop and commercialize potential Alzheimer's disease treatment

Eli Lilly and Company and AstraZeneca today announced an agreement to co-develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease. [More]